Publications by authors named "A Bonzano"
Article Synopsis
- Fluoropyrimidines (FP) are a key chemotherapy for colorectal cancer (CRC) but can lead to underreported heart damage, known as FP-induced cardiotoxicity (FIC).
- A study monitored 129 CRC patients for FIC, finding that 15.5% experienced symptoms like chest pain and dyspnoea, although most had no significant ECG changes.
- No specific risk factors were strongly linked to FIC, aside from alcohol consumption in females, and no effective circulating biomarkers were identified for predicting FIC, emphasizing the need for careful symptom monitoring during FP treatment.
Aims: Risk stratification in patients with advanced chronic heart failure (HF) is an unmet need. Circulating microRNA (miRNA) levels have been proposed as diagnostic and prognostic biomarkers in several diseases including HF. The aims of the present study were to characterize HF-specific miRNA expression profiles and to identify miRNAs with prognostic value in HF patients.
View Article and Find Full Text PDFPrevious studies showed that the hepatocyte growth factor (HGF)-Met receptor axis plays long-lasting cardioprotection against doxorubicin anti-cancer therapy. Here, we explored the mechanism(s) underlying the HGF protective effect. DNA damage was monitored by histone H2AX phosphorylation and apoptosis by proteolytic cleavage of caspase 3.
View Article and Find Full Text PDFBackground And Purpose: Doxorubicin anti-cancer therapy is associated with cardiotoxicity, resulting from DNA damage response (DDR). Hepatocyte growth factor (HGF) protects cardiomyocytes from injury, but its effective use is compromised by low biodistribution. In this study, we have investigated whether the activation of the HGF receptor-encoded by the Met gene-by an agonist monoclonal antibody (mAb) could protect against doxorubicin-induced cardiotoxicity.
View Article and Find Full Text PDFBackground: Angiotensin Converting Enzyme inhibitors (ACEis) and beta-blockers (BB) are suggested to prevent and treat trastuzumab-related cardiac toxicity. We performed a prospective clinical trial in women experiencing mild cardiac toxicity (MCT) while on adjuvant treatment with trastuzumab.
Methods: MCT was defined as an asymptomatic absolute decrease in LVEF of ≥ 10 percentage units to >50%.